FindTrial
Sign In

Vemurafenib and Cobimetinib

DRUG4 trials

Sponsors

Grupo Español Multidisciplinar de Melanoma, American Society of Clinical Oncology, Radboud University Medical Center, Inova Health Care Services

Conditions

Advanced Solid TumorsLymphoma, Non-HodgkinMelanomaMelanoma, Malignant, of Soft PartsMultiple MyelomaStage IIIB-C Melanoma

Phase 2

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
CompletedNCT02583516
Grupo Español Multidisciplinar de MelanomaMelanoma
Start: 2015-06-30End: 2019-09-30Updated: 2020-02-17
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingNCT02693535
American Society of Clinical OncologyAdvanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Start: 2016-03-14End: 2028-12-31Target: 4200Updated: 2026-05-29
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
NCT02968303
Radboud University Medical CenterMelanoma, Malignant, of Soft Parts
Start: 2017-01-27End: 2023-10-31Target: 200Updated: 2020-06-05
ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
WithdrawnNCT03005639
Inova Health Care ServicesStage IIIB-C Melanoma
Start: 2017-06-01End: 2018-02-24Updated: 2018-05-09

Related Papers

Combination of vemurafenib with cobimetinib in <i>BRAF</i> V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.
Journal of Clinical Oncology2026-05-28
Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2026-05-27
Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.
Journal of Clinical Oncology2026-05-27
Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2026-01-10
Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
2025-07-03
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-05-281 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with <i>ERBB2/3</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-05-28
Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-01-273 citations
Afatinib in patients (pts) with solid tumors with neuregulin 1 (<i>NRG1</i>) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-06-011 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with <i>ERBB2</i>or<i> ERBB3</i>amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-06-01
Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal of Clinical Oncology2024-06-01
Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with <i>BRCA1/2</i> mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-01-201 citations
Abemaciclib in patients (pts) with esophageal cancer (EC) with <i>CDKN2A</i> loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-01-20
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial
Clinical Trials2023-07-257 citations
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
Temsirolimus (T) in patients (pts) with solid tumors with <i>PIK3CA </i>mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
Talazoparib (Tala) in patients (pts) with solid tumors with <i>BRCA1/2 </i>mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BMC Cancer2023-02-2223 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-01-247 citations
Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-01-247 citations

22 more papers not shown